Brind.

Xoma is acquiring Mural Oncology, a company that was previously spun out of Alkermes.

2 reports, 2 independent Updated Aug 21
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Xoma is acquiring Mural Oncology, a company that was previously spun out of Alkermes.

Who's involved

What this event is mainly about
MuralAlkermes

Keep exploring

The entities involved

  • Mural

    MURAL isn't just for designers

    Nothing else this week.

  • Alkermes

    company

    Nothing else this week.

Coverage

Newest first; wire copies grouped
  • BioPharma DiveXoma, a drug royalty specialist, buys another ‘zombie’ biotech This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive ne
  • GlobeNewswireMural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share WALTHAM, Mass. and DUBLIN and EME